Oncology

Struggling biotech Tempest Therapeutics adds finance and medical heavyweights to its board. Is this a strategic reset or a last-ditch effort to survive?

A new class of doctor is bridging the gap between lab and patient. Meet the physician-scientists tackling deadly diseases with revolutionary new approaches.

Beyond the headlines of a new cancer therapy, French biotech Oncovita is executing a masterclass in strategy, leveraging a modified measles virus and AI.

A pharma revolution is brewing for Generalized Anxiety Disorder. As prevalence soars, novel therapies targeting new neural pathways promise to upend the market.

With record device sales providing a solid financial base, RenovoRx nears a critical milestone in its high-stakes Phase III trial for a new pancreatic cancer therapy.

A crucial CAP accreditation for its advanced CNS cancer test positions Plus Therapeutics to unlock new markets and redefine patient care with precision diagnostics.

A top Virginia cancer practice has been chosen to train US doctors in a breakthrough radiopharmaceutical therapy, a strategic move to break a key training bottleneck.

Syndax Pharmaceuticals secures a $250M war chest via convertible notes. We decode the deal, what it means for its cancer drugs, and why it's a savvy move.

As Insulet unveils pivotal data, a deeper look reveals a strategy to not just improve tech, but to fundamentally change the daily reality of diabetes.

With its world-first gastric cancer drug heading for approval, Innovent Biologics isn't just offering new hope—it's executing a masterclass in strategic leverage.

Barcelona's Ona Therapeutics secures $86.6M to advance its novel antibody-drug conjugates, moving beyond existing treatments to tackle resistant cancers.

ADC Therapeutics' lymphoma drug ZYNLONTA shows promise in a Phase 3 trial, but a concerning safety signal in older patients complicates its path to market.

dltHub's recent Snowflake award isn't just a trophy. It signals a tectonic shift where AI automates the complex plumbing of the digital economy.

The market for T-cell malignancy treatments is set to surpass $1.8B, fueled by a pipeline of innovative drugs aiming to meet vast unmet patient needs.

The struggling biopharma secures cash, but its creative financing deal could dilute existing shareholder value by over 30%. A deep dive into the high-stakes world of biotech funding.

With a potential $4 billion on the line, CytomX and Regeneron are building a new class of cancer therapies designed to act like autonomous agents in the body.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

A recent FDA approval for a generic cancer drug adds to a growing market, revealing the strategic alliances redefining healthcare access.

New data on Syndax Pharma's Revuforj shows a 90% survival rate in a high-risk leukemia group, signaling a potential paradigm shift and major market catalyst.

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?